17 Dec



Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419 Class A Ordinary Shares, at a public offering price of $15.80 per share. The aggregate gross proceeds to Aptorum from the offering were $12,030,420, before deducting underwriting discounts and commissions and other offering expenses. While certain selling shareholders are offering to resell up to 1,595,235 Class A Ordinary Shares subject to certain lock-up periods, as applicable, none of the gross proceeds of the IPO will be used to purchase the selling shareholders’ securities nor will the Company receive any proceeds from the selling shareholders’ resale. The shares are expected to commence trading on The NASDAQ Global Market on December 18, 2018 at any time between 11:00 a.m. to 12:00 p.m. ET, under the ticker symbol “APM.”

Boustead Securities, LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets Limited acted as co-underwriters for the offering.

A registration statement has been filed with the SEC and became effective on December 3, 2018. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Boustead Securities, LLC, email: offerings@boustead1828.com or by calling +1 (949) 502-4409 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aptorum Group Limited

We are a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. We have obtained exclusive licenses for our technologies. In addition, we are also developing certain proprietary technologies as product candidates. We are pursuing therapeutic and diagnostic projects (including projects seeking to use extracts or derivatives from natural substances to treat diseases) in neurology, infectious diseases, gastroenterology, oncology and other disease areas. We also have projects focused on surgical robotics. In addition, we opened a medical clinic, AML Clinic, in June 2018. Its initial focus is on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population. For more information about the Company, please visit www.aptorumgroup.com.

About Boustead Securities, LLC

Boustead Securities, LLC ("Boustead") is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead's core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit www.boustead1828.com.

About China Renaissance Securities (Hong Kong) Limited

China Renaissance (“CR”) is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new economy entrepreneurs and investors globally. CR has offices in Beijing, Shanghai, Hong Kong and New York, with approximately 600 employees. As of March 31, 2018, CR had advised on approximately 700 transactions worth over US$100 billion since the inception, and CR had AUM of approximately US$4.1 billion in new economy investments. For more information, visit www.huaxing.com.

About AMTD Global Markets Limited

AMTD Global Markets Limited (“AMTD”) is a Hong Kong-based comprehensive financial institution dedicated to serving and bridging capital and resources across mainland China, Hong Kong and the globe. As one of the largest Hong Kong-based non-bank financial institution, AMTD has been widely recognized as a pre-eminent capital markets player with leading cross-border investment banking capabilities in Asia. Founded in 2003, AMTD has a long history of promoting technological innovations and the development of New Economy sectors, especially in the fields of FinTech, Artificial Intelligence and Healthcare. For more information, visit www.amtdgroup.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding listing on the NASDAQ Global Market and the completion of the IPO are forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, risks and uncertainties related to the satisfaction of the customary closing conditions related to the IPO and the listing on NASDAQ. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof unless required by the applicable laws, regulations or rules.

At the Company:
Sabrina Khan, CFO
Aptorum Group Limited
Phone: +852 2117 6611
Email: investor.relations@aptorumgroup.com

06 Dec





如上所述,公司已向美國證券交易委員會提交了與註冊證券(文件號:333-227198)有關的註冊聲明。此聲明已於2018年12月3日宣佈生效。此次發售僅通過書面招股說明書進行,該招股說明書為有效註冊聲明的一部分。您可以通過訪問美國證券交易委員會網站www.sec.gov上的EDGAR免費獲得招股說明書的副本。或者,您亦可以向寶德證券有限公司索取本次發行有關的招股說明書的副本,電子郵件請致:offerings@boustead1828.com 或致電+1 (949) 502-4409,或郵件請致:Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.



我們是一家以香港為基地、處於臨床前階段的製藥企業。目前正致力推進一系列醫療及診斷科技的研發和商品化,以應對未被滿足的醫療需求。我們已獲得我們技術的獨家許可。此外,我們還在開發某些專有技術作為候選產品。在神經內科,傳染病,胃腸科,腫瘤學和其他疾病領域,我們正在尋求治療和診斷項目(包括尋求使用天然提取物或其衍生物治療疾病的項目)。我們還有專注於手術機器人的項目。另外,我們於2018年6月創建了一家醫療診所,名為AML 診所,其最初針對的是治療由現代久坐不動的生活方式和人口老齡化引起的慢性病。更多信息,請瀏覽:www.aptorumgroup.com.









Sabrina Khan 首席財務總監
電話: +852 2117 6611
電子郵箱: investor.relations@aptorumgroup.com



This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.